Institutional Innovation in Devices
This article was originally published in Start Up
These days, medtech investors need to be much more selective about how they spend their capital. In pursuit of steady streams of early-stage opportunities with a high likelihood of success, VCs are establishing closer ties with entprepreneurs and executives they feel can do it again.
You may also be interested in...
After a lull, or at least a single-minded focus on femtosecond lasers for a time, refractive surgery has gotten exciting again: the drive to spectacle-free outcomes for cataract patients (who have aged-out of their eligibility for other refractive procedures) is calling for solutions that offer precision and accuracy at every stage of treatment. Start-ups coming up with the solutions will be serving some gigantic markets.
Best of the Blog is a monthly column highlighting the best of our free online content at www.windhover.com/blog. In June and early July Windhover's editorial staff posted more than seventy articles to the site, covering biopharma, device and diagnostics R&D, business development, regulatory and commercial news. Highlights included a discussion of biotech exit strategies and a peek at the results of a survey about the worth of advice from investment bankers. Here are a few of our favorite blog posts for stories not covered elsewhere in this month's START-UP.
Publicly traded QLT Inc. is trying to capture lightning in a bottle; it has acquired the second company spawned by ForSight Labs, the incubator created by The Foundry. The still unnamed company has developed drug-eluting punctual plugs that QLT believes could challenge the $6 billion eye-drop industry.